Article Text

Download PDFPDF
Desmopressin in the treatment of daytime urinary frequency in patients with multiple sclerosis
  1. Patricia A Hoverd,
  2. Clare J Fowler
  1. Department of Uro-Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK
  1. Dr Clare J Fowler, Department of Uro-Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK. Telephone 0044 171 837 3611 extension 3418; fax 0044 171 813 4587; emailc.fowler{at}ion.ucl.ac.uk

Abstract

Twenty two patients with multiple sclerosis, complaining of frequency of day time micturition, completed a double blind crossover trial of desmopressin (DDAVP nasal spray) versus placebo. There was a significant decrease in micturition frequency in the 6 hour post-treatment period from 3.1 voids after placebo to 2.4 voids and a significant reduction in urinary volume after desmopressin. Eighty per cent of patients preferred the active treatment phase. Mean 24 hour urinary volume did not differ between active and placebo treatments and patients did not complain of increased night time frequency. Transient symptoms of hyponatraemia occurred in one patient but these resolved within 48 hours of stopping desmopressin. There were otherwise no side effects and mean serum sodium concentrations of the group remained unchanged throughout the study. The clinical indications for prescribing daytime desmopressin are discussed and the importance of patient compliance stressed.

  • multiple sclerosis
  • bladder dysfunction
  • urinary frequency
  • desmopressin

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes